AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smyth, R. D.
Right arrow Articles by Hottendorf, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, R. D.
Right arrow Articles by Hottendorf, G. H.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1979 November; 16(5): 615-621
Copyright © 1979, American Society for Microbiology. All Rights Reserved.

Clinical Pharmacokinetics and Safety of High Doses of Ceforanide (BL-S786R) and Cefazolin

Robert D. Smyth, Morris Pfeffer, Aaron Glick Donald, R. Van Harken and Girard H. Hottendorf

1 Department of Drug Metabolism and Pharmacokinetics and Department of Clinical Research, Bristol Laboratories, Syracuse, New York 13201

ABSTRACT

The pharmacokinetics and safety of ceforanide and cefazolin were compared in normal subjects after 30-min intravenous infusions of 2-, 3-, and 4-g single doses and 4-g twice-daily doses for 10 days. No significant differences were observed in plasma-renal pharmacokinetic parameters between single and multiple doses of ceforanide. Half-life (t1/2, 2.8 h), plasma clearance (Clp, 48 ml/min per 1.73 m2), and renal clearance (Cl0–12hr, 47 ml/min per 1.73 m2; tubular secretion, 44%, and glomerular filtration, 56%) did not change with increased dose or on multiple dosing. No significant change was observed in t1/2 (1.9 h), area under the plasma concentration-time curve, Clr (60 ml/min per 1.73 m2; tubular secretion, 80%, and glomerular filtration, 20%), or Clp (75 ml/min per 1.73 m2) for 4-g single doses compared with twice-daily administration of cefazolin. A small increase in cefazolin clearance was observed when plasma concentrations were greater than 100 µg/ml, when the single dose was increased from 2 to 4 g; this was a result of the decrease in percentage of plasma protein binding and increased renal clearance due to increased glomerular filtration. The increase in renal clearance resulted in a lack of linear proportionality of the plasma area under the curve with dose over a range of 2 to 4 for both cephalosporins, although this effect was much less marked with ceforanide. Both compounds were well tolerated both locally and systemically. There was no evidence of any change in renal function based on clearances of drug, p-aminohippuric acid, or creatinine, and other standard clinical parameters.


Antimicrob Agents Chemother. 1979 November; 16(5): 615-621
Copyright © 1979, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1979 by the American Society for Microbiology. All rights reserved.